Immunocore Holdings Ltd (IMCR) is a Healthcare · Biotechnology company listed on NASDAQ. Price $32.00 (-0.93%), Market cap $1.50B, 52-week low–high $27.91 ~ $40.22.
Immunocore Holdings plc, together with its subsidiaries, engages in the development and commercialization of immunomodulating medicines for patients with cancer, infectious diseases, and autoimmune disease in the United States, Europe, and internationally. The company offers KIMMTRAK for the treatment of unresectable or metastatic uveal melanoma. It also develops oncology programs, including tebentafusp which is in Phase 3 clinical trial for the treatment of advanced cutaneous melanoma and adjuvant uveal melanoma; brenetafusp which is in Phase 3 clinical trial for the treatment of first-line advanced cutaneous melanoma and in Phase 1/2 clinical trial for the treatment of various tumor types;
Financial statements, price targets, institutional (13F) holdings and related news for Immunocore Holdings Ltd are updated in real time on BlackAll Trade.
Immunocore Holdings Ltd trades at $32.00 (-0.93%). Real-time quotes and charts are available on BlackAll Trade.
Immunocore Holdings Ltd has a market cap of about $1.50B.
Immunocore Holdings plc, together with its subsidiaries, engages in the development and commercialization of immunomodulating medicines for patients with cancer, infectious diseases, and autoimmune di